Liren Tang
Vorstandsvorsitzender bei Welichem Biotech, Inc.
Profil
Liren Tang is currently the President & Chief Executive Officer at Welichem Biotech, Inc. since 2009.
Previously, he worked as a Principal at Vancouver Coastal Health Research Institute.
Dr. Tang holds a doctorate degree from the University of British Columbia.
Aktive Positionen von Liren Tang
| Unternehmen | Position | Beginn |
|---|---|---|
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Vorstandsvorsitzender | 18.11.2009 |
Ehemalige bekannte Positionen von Liren Tang
| Unternehmen | Position | Ende |
|---|---|---|
Vancouver Coastal Health Research Institute
 Vancouver Coastal Health Research Institute Miscellaneous Commercial ServicesCommercial Services Vancouver Coastal Health Research Institute operates as a health research institute. It offers orientation, clinical trials administration, intellectual property, and community research services. The company is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Ausbildung von Liren Tang
| University of British Columbia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
Vancouver Coastal Health Research Institute
Vancouver Coastal Health Research Institute Miscellaneous Commercial ServicesCommercial Services Vancouver Coastal Health Research Institute operates as a health research institute. It offers orientation, clinical trials administration, intellectual property, and community research services. The company is headquartered in Vancouver, Canada. | Commercial Services |
